April 12, 2024

Advances in pharmacotherapy for myelofibrosis: what is the current state of play?

Key Points

Key points are not available for this paper at this time.

Abstract

The introduction of the first JAK inhibitor (JAKi) ruxolitinib 10 years ago represented a pivotal advancement in myelofibrosis (MF) treatment, mostly in terms of spleen and symptoms response. Nowadays three more JAKi, fedratinib, pacritinib, and momelotinib, are available for both ruxolitinib-resistant and naïve patients. Moreover, many drugs are currently being investigated, both alone and in combination with JAKi.

Demander à l'IA

Bookmark

Cite This Study

Tiribelli et al. (Fri,) studied this question.

synapsesocial.com/papers/68e6f722b6db643587671e8f https://doi.org/https://doi.org/10.1080/14656566.2024.2354461

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms2017 · 284 citations
2Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis2020 · 18 citations
3Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study2020 · 30 citations
4Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Myelofibrosis2023 · 11 citations
5Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-naïve patients with myelofibrosis: Updated results from XPORT-MF-034.2023 · 4 citations

Demander à l'IA

Bookmark